Absci
Absci
AI-powered drug discovery and development platform for biologics.
About
Absci leverages generative AI and synthetic biology to discover novel biology and create better biologics. Their AI Drug Creation Platform designs differentiated biologics, such as antibodies targeting prolactin receptors for hair regrowth, and partners with leaders across pharma, tech, and academia to develop therapeutics against challenging targets. Absci aims to accelerate the delivery of life-changing medicines to patients.
Key facts
- Website
- absci.com
- Headquarters
- Vancouver, United States
- Founded
- 2011
- Employees
- 173
- Total funding
- $101M (Series C)
- Valuation
- Private
- Business model
- B2B
- Tags
- BiotechDrug DiscoveryAI-Driven Protein DesignFoundation ModelGenerative AI
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 21 Jul 2021 | Series C | $56M | Foresite Capital |
| 23 Jan 2020 | Series B | $30M | Amazon Alexa Fund |
| 19 Sept 2018 | Series A | $13M | 7wire Ventures |
| 1 Mar 2017 | Seed | $2M | - |
Tech stack
Detected on absci.com, last scanned 10 Sept 2026. Run your own scan
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- Support
- Zendesk
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Google Workspace
Add first review
Frequently asked
How much funding has Absci raised?
Absci has raised a total of $101M in funding. The most recent round on record is Series C.
How many employees does Absci have?
Absci has approximately 173 people on record.